Welcome to our dedicated page for Guardant Health news (Ticker: GH), a resource for investors and traders seeking the latest updates and insights on Guardant Health stock.
Guardant Health (GH) is a leader in precision oncology, pioneering non-invasive liquid biopsy tests for cancer detection and monitoring. This dedicated news hub provides investors and healthcare professionals with timely updates on the company's financial performance, clinical advancements, and strategic initiatives.
Access authoritative coverage of earnings reports, regulatory milestones, and technology innovations shaping cancer diagnostics. Our curated collection includes press releases on clinical trial results, partnership announcements, and peer-reviewed research developments directly from Guardant Health's communications.
Key updates cover FDA clearances for diagnostic assays, global commercialization efforts, and data partnerships advancing precision medicine. Stay informed about developments in molecular residual disease detection, expanded test indications, and reimbursement progress affecting healthcare adoption.
Bookmark this page for consolidated access to verified information about liquid biopsy advancements and GH's role in transforming cancer care through genomic insights. Check regularly for objective reporting on developments impacting both clinical practice and investment considerations.
Guardant Health (Nasdaq: GH) will showcase significant data on its blood tests at the virtual 2021 ASCO Gastrointestinal Cancers Symposium from January 15-17, 2021. The presentations will focus on the clinical utility of Guardant’s liquid biopsy technology in screening and treating colorectal cancer. CEO Helmy Eltoukhy emphasized the importance of these tests in tracking treatment responses and early detection of cancer recurrence. Notable highlights include the Guardant Reveal™ test and the LUNAR-2 ECLIPSE trial aimed at early detection in average-risk adults.
Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P. Morgan Virtual Healthcare Conference, scheduled for January 11 at 7:50 a.m. PT / 10:50 a.m. ET. The event will feature a presentation by the company's management, accessible via a live and archived webcast on their website. Guardant Health specializes in precision oncology, offering blood tests and analytics that enhance cancer care. Their platforms, including Guardant360® and GuardantOMNI®, focus on advanced cancer treatment and early detection strategies.
Guardant Health, Inc. (Nasdaq: GH) has appointed Michael Bell as its new Chief Financial Officer (CFO), effective January 5, 2021. He succeeds Derek Bertocci, who retired after four years with the company. Bell brings over 25 years of finance experience from companies such as CareDx and Novartis Diagnostics. CEO Helmy Eltoukhy emphasized Bell's capability to enhance the company's financial operations and support its goal of transforming cancer care. Guardant Health specializes in precision oncology through proprietary blood tests and advanced analytics.
Guardant Health, Inc. (Nasdaq: GH) presented new findings at the 2020 Virtual San Antonio Breast Cancer Symposium, showcasing its GuardantINFORM™ platform. This tool provides critical insights into treatment responses in patients with ER-positive, HER-2 negative metastatic breast cancer, emphasizing the issue of treatment resistance. Key abstracts revealed molecular tumor evolution and resistance mechanisms. With over 135,000 patient data points in its database, GuardantINFORM aims to enhance targeted drug development and clinical trials in oncology.
Guardant Health has priced an offering of $1 billion in 0% convertible senior notes due 2027, set to settle on November 19, 2020. The notes will not accrue interest and have an initial conversion rate of 7.1523 shares per $1,000, representing a conversion price of around $139.82, a 34% premium over its recent stock price. The company expects net proceeds of approximately $984.3 million, intended for corporate purposes, including research and development and potential acquisitions. Additionally, capped call transactions are in place to reduce dilution from the notes' conversion.
Guardant Health (Nasdaq: GH) announced a private offering of $1 billion in convertible senior notes due 2027, with an additional $150 million option for initial purchasers. The notes will mature on November 15, 2027, and can be converted into cash or stock. Proceeds will fund capped call transactions and general corporate purposes, including R&D and potential acquisitions. This offering is subject to market conditions, and the notes are not registered under the Securities Act. Guardant Health is a leader in precision oncology, focusing on innovative blood tests for cancer detection.
Guardant Health (GH) reported a 23% revenue increase to $74.6 million for Q3 2020, driven by a 16% rise in precision oncology revenue ($60.4 million). Development services surged 63% to $14.2 million. Clinical test volume rose 28% to 16,950, but biopharmaceutical tests fell 42% to 3,071. The company received FDA approval for Guardant360® CDx, the first liquid biopsy for comprehensive cancer profiling. Despite a gross profit rise to $53.4 million, operating expenses ballooned 113% to $127.6 million, leading to a net loss of $77.7 million ($0.78 per share). Guidance for 2020 remains unprovided due to COVID-19 uncertainties.
Guardant Health, Inc. (Nasdaq: GH) will release its third-quarter 2020 financial results on November 5, 2020, after market closure. A conference call will follow at 1:30 p.m. PT. Investors can access the live audio webcast in the 'Investors' section of the company website. Guardant Health specializes in precision oncology, providing advanced blood tests like Guardant360 and GuardantOMNI to improve cancer patient outcomes and reduce healthcare costs. The company focuses on all cancer care stages, including early detection and selection of treatments for advanced cancer patients.
Guardant Health, Inc. (Nasdaq: GH) has completed a public offering of 7.7 million shares of common stock, priced at $102.00 per share, including 700,000 shares from the underwriter's option. Notably, Guardant Health did not sell any shares nor receive proceeds from this offering, which was conducted by SoftBank Investment Advisers. The offering was made under an automatic shelf registration statement filed with the SEC, which became effective upon filing. J.P. Morgan Securities LLC served as the book-running manager for this offering.
Guardant Health has announced a public offering of 7,000,000 shares of its common stock priced at $102.00 per share, with the offering managed by J.P. Morgan Securities LLC. The shares are being sold by SoftBank Investment Advisers, and Guardant Health will not receive any proceeds from this sale. An additional option for underwriters to purchase up to 700,000 shares is also available. The offering is expected to close on October 9, 2020, pending customary closing conditions. This public offering is registered under Form S-3 with the SEC.
